A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors

By afschroeder • March 1, 2026

Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira AI, Sommerhalder D, Garrido-Laguna I, Hong DS. A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors. NPJ Precis Oncol. 2026 Feb 28. doi: 10.1038/s41698-026-01340-1. Epub ahead of print. PMID: 41764244.

Tags: Hematology/Oncology, Publications

Social wellbeing, loneliness, and symptom burden in head and neck cancer survivors: a latent class analysis

Brauer ER, Choi KR, Petersen L, Ganz PA, St John MA, Wong DJ, Martin EJ. Social wellbeing, loneliness, and symptom burden in head and neck[...]

Achieving timely treatment for early-stage non-small cell lung cancer: Factors associated with delayed surgical resection and proposed quality benchmarks

Tupper HI, Bhattacharjee J, Sarovar V, Amara D, Schmittdiel JA, Quesenberry CP, Cummings AL, Velotta JB, Sakoda LC. Achieving timely treatment for early-stage non-small cell[...]

Impact of UGT1A1*28 polymorphism in patients with metastatic pancreatic ductal adenocarcinoma treated with NALIRIFOX in the NAPOLI 3 trial

Abdelrahim M, Khan G, Hatoum H, Zervoudakis A, Dayyani F, Zhang L, Li J, Maxwell F, O'Reilly EM, Wainberg ZA, Bullock A. Impact of UGT1A1*28polymorphism in[...]